Leiden, The Netherlands, May 28, 2010. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announces that all items on the agenda of today's Annual General Meeting of Shareholders (AGM) have been approved by the Shareholders.

At the AGM, Dr. Sijmen de Vries, Chief Executive Officer of Pharming, presented the 2009 results and the outlook of the Company for 2010. This presentation can be found on the Pharming website. Main topics at the meeting were financing of the Company, the progress on the European Marketing Authorization Application (MAA) for Rhucin and the anticipated Day 210 EMA opinion on the MAA by end of June, followed by the adoption of the opinion and the granting of the Marketing Authorisation at Day 277 by the European Commission in Q3 2010. Management confirmed its confidence on a positive outcome of the MAA process.

At the AGM, the majority of Shareholders voted in favour of the proposed items on the agenda. The agenda included the proposal to increase the annual remuneration of Pharming's CEO and the members of the Board of Supervisory Directors. Both the members of the Board of Supervisory Directors, as well as Pharming's CEO, voluntarily declined the proposed increases.

Mr. Jaap Blaak, Chairman of Pharming's Board of Supervisory Directors, said: "Securing the Company's future and long-term value for our shareholders is our first priority. Achieving financial stability is vital in order for Pharming to reach its corporate goals. We highly appreciate management's efforts to improve the financial situation of the Company and the position of the Company as a whole."